A functional role for Smad7 in sustaining colon cancer cell growth and survival

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Stolfi, C ^a   De Simone, V ^a   Colantoni, A ^a   Franze E ^a   Ribichini, E ^a   Fantini, M C ^a   Caruso, R ^a   Monteleone, I ^a   Sica, G S ^a   Sileri, P ^a   Macdonald, T T ^b   Pallone, F ^a   Monteleone, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apcmin + mice; cell cycle; organ culture; xenograft

Indexed keywords

CYCLIN DEPENDENT KINASE 2; INITIATION FACTOR 2ALPHA; PHOSPHATASE; PROTEIN CDC25A; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; CDC25 PHOSPHATASES; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 2; DISEASE MODELS, ANIMAL; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; GENES, RAG-1; GENETIC THERAPY; HCT116 CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TIME FACTORS; TRANSFECTION;

EID: 84896744270     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.49     Document Type: Article

References (23)

1. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-378.
2. Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol 2003; 42: 809-815.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
4. Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res 2010; 70: 1479-1485.
5. Thompson CL, Plummer SJ, Acheson LS, Tucker TC, Casey G, Li L. Association of common genetic variants in SMAD7 and risk of colon cancer. Carcinogenesis 2009; 30: 982-986.
6. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L et al. SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 2003; 104: 446-449.
7. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-635.
8. Briones-Orta MA, Tecalco-Cruz AC, Sosa-Garrocho M, Caligaris C, Macias-Silva M. Inhibitory Smad7: Emerging roles in health and disease. Curr Mol Pharmacol 2011; 4: 141-153.
9. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783.
10. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004; 11: 1043-1051.
11. Busino L, Chiesa M, Draetta GF, Donzelli M. Cdc25A phosphatase: Combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 2004; 23: 2050-2056.
12. Tomko RJ Jr, Lazo JS. Multimodal control of Cdc25A by nitrosative stress. Cancer Res 2008; 68: 7457-7465.
13. Wek RC, Jiang HY, Anthony TG. Coping with stress: EIF2 kinases and translational control. Biochem Soc Trans 2006; 34: 7-11.
14. Issa AY, Volate SR, Muga SJ, Nitcheva D, Smith T, Wargovich MJ. Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. Carcinogenesis 2007; 28: 1978-1984.
15. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
16. Waldner MJ, Neurath MF. The molecular therapy of colorectal cancer. Mol Aspects Med 2010; 31: 171-178.
17. Pulaski L, Landstrom M, Heldin CH, Souchelnytskyi S. Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-beta-dependent signaling but affects Smad7-dependent transcriptional activation. J Biol Chem 2001; 276: 14344-14349.
18. Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 2002; 10: 483-493.
19. Boyer Arnold N, Korc M. Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem 2005; 280: 21858-21866.
20. Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012; 20: 870-876.
21. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-609.
22. Monteleone G, Franchi L, Fina D, Caruso R, Vavassori P, Monteleone I et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-Aminosalicylic acid in colon cancer cells. Cell Death Differ 2006; 13: 202-211.
23. Becker C, Fantini MC, Wirtz S, Nikolaev A, Kiesslich R, Lehr HA et al. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut 2005; 54: 950-954.